AcelRx Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) was the recipient of unusually large options trading activity on Tuesday. Traders purchased 6,179 call options on the company. This is an increase of approximately 1,040% compared to the typical volume of 542 call options.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA boosted its stake in shares of AcelRx Pharmaceuticals by 350.3% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 19,215 shares of the specialty pharmaceutical company’s stock valued at $27,000 after buying an additional 14,948 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in shares of AcelRx Pharmaceuticals by 39.3% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 21,283 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 6,000 shares during the last quarter. Two Sigma Advisers LP purchased a new position in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at approximately $48,000. Edmonds Duncan Registered Investment Advisors LLC boosted its stake in shares of AcelRx Pharmaceuticals by 38.5% during the 3rd quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 36,000 shares of the specialty pharmaceutical company’s stock valued at $51,000 after buying an additional 10,000 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of AcelRx Pharmaceuticals by 72.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 52,665 shares of the specialty pharmaceutical company’s stock valued at $75,000 after buying an additional 22,211 shares during the last quarter. Hedge funds and other institutional investors own 24.45% of the company’s stock.

NASDAQ ACRX opened at $1.99 on Thursday. The stock has a market cap of $180.05 million, a PE ratio of -3.55 and a beta of 1.16. AcelRx Pharmaceuticals has a fifty-two week low of $0.70 and a fifty-two week high of $2.21. The business has a 50 day moving average price of $1.37 and a two-hundred day moving average price of $1.38.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings results on Tuesday, November 10th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.02). The business had revenue of $1.37 million during the quarter, compared to analysts’ expectations of $6.15 million. Equities analysts anticipate that AcelRx Pharmaceuticals will post -0.48 EPS for the current fiscal year.

Separately, Zacks Investment Research downgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 12th. Two analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $4.52.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.

Featured Article: Is the Dow Jones Industrial Average (DJIA) still relevant?

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.